I too wish that we would have heard something about efficacy, but probably too soon to say too much. Now that they have found the maximally tolerated dose (MTD), things should move much faster. Patients that were in the dose escalation portion and new patients added will be at the optimized dose (one dose lower than the MTD I think, unless they decide to do some intermittent dosing as well). So there will be many more patient observations opportunities coming in the future to add to the limited numbers during the earlier portion of the trial.

Intestingly, one of the goals of the ZEN-3694 stand alone and enzalutamide combo trials was to determine the recommended phase 2 dose. I wonder how much longer the ZEN-3694 stand alone Phase 1 trial must go before proceeding to Phase 2? Will the Phase 2 be a new trial, or will they amend the current trial to be a Phase 1/2, which I've seen for other similar trials?

There are presentations in January and February, so perhaps in 1-2 months time these questions will be answered and hopefully some glimpse of efficacy will be revealed.

BearDownAZ